← Back to Search

Monoclonal Antibodies

Lanadelumab for Angioedema

Phase 3
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose and post-dose at days 4, 14, 28, 56, 84, 112, 140, 168 and 182
Awards & highlights

Summary

This trial tests if lanadelumab injections can prevent swelling attacks in teenagers and adults with a specific type of swelling disorder. The medication works by blocking a protein that causes these attacks. Participants will receive regular injections over several months.

Eligible Conditions
  • Angioedema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose and post-dose at days 4, 14, 28, 56, 84, 112, 140, 168 and 182
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose and post-dose at days 4, 14, 28, 56, 84, 112, 140, 168 and 182 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Investigator-Confirmed Angioedema Attacks During the Treatment Period of Day 0 Through Day 182
Secondary study objectives
Number of Investigator-Confirmed Angioedema Attacks During the Presumed Steady State Period of Day 70 Through Day 182
Angioedema
Number of Investigator-Confirmed Moderate or Severe Angioedema Attacks During the Treatment Period of Day 0 Through Day 182
+12 more

Side effects data

From 2021 Phase 3 trial • 21 Patients • NCT04070326
18%
Nasal congestion
18%
Injection site erythema
18%
Injection site pain
18%
Joint injury
9%
Injection site injury
9%
Injection site reaction
9%
Nasopharyngitis
9%
Asymptomatic COVID-19
9%
Skin laceration
9%
Headache
9%
Oropharyngeal discomfort
9%
Oropharyngeal pain
9%
Erythema
9%
Skin abrasion
9%
Abdominal pain
9%
Administration site pain
9%
Rhinitis
9%
Adenoiditis
9%
Affect lability
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lanadelumab 150 mg, q4wks
Lanadelumab 150 mg, q2wks

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lanadelumab 300mgExperimental Treatment1 Intervention
Participants received 300 mg of lanadelumab solution in a prefilled syringe (PFS) as SC injection once (q2w) for up to 6 months.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo-matching lanadelumab subcutaneous (SC) injection once every 2 weeks (q2w) for up to 7 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lanadelumab
2021
Completed Phase 3
~770

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,227 Previous Clinical Trials
4,222,428 Total Patients Enrolled
14 Trials studying Angioedema
1,297 Patients Enrolled for Angioedema
ShireLead Sponsor
456 Previous Clinical Trials
97,201 Total Patients Enrolled
43 Trials studying Angioedema
6,052 Patients Enrolled for Angioedema
Takeda Development Center Americas, Inc.Industry Sponsor
56 Previous Clinical Trials
11,963 Total Patients Enrolled
5 Trials studying Angioedema
3,381 Patients Enrolled for Angioedema
~14 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top